Price (90d)
$75.40Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $199.09M | $30.13M | $1.18 |
| 2024 | $109.95M | $5.11M | $0.29 |
| 2023 | $72.86M | $63.17M | $4.36 |
| 2022 | $51.78M | $-6.36M | $-0.44 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $0.41 per share
Typical surprise -45.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.40 vs $0.53miss
- Wed, May 6$0.23 vs $0.70miss
- Wed, Feb 25$0.24 vs $0.62miss
- Wed, Nov 12$0.26 vs $0.48miss
- Wed, Aug 6$0.24 vs $0.39miss
- Wed, May 7$0.20 vs $0.34miss
Estimates and results for LB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.59
- Implied price
- $77.91
- Return from $78.69
- -0.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $38.74 — -50.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 35 | 42 | 49 | 56 | 63 |
|---|---|---|---|---|---|
| -2.0% | -15.3% | -12.2% | -9.4% | -7.0% | -4.8% |
| 3.0% | -11.0% | -7.7% | -4.8% | -2.2% | 0.1% |
| 8.0% | -6.7% | -3.2% | -0.2% | 2.5% | 4.9% |
| 13.0% | -2.4% | 1.3% | 4.4% | 7.2% | 9.8% |
| 18.0% | 1.9% | 5.7% | 9.0% | 12.0% | 14.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (2)
- News (RSS)seekingalpha·4d ago·Negative
LB Pharmaceuticals Inc GAAP EPS of -$1.71 misses by $0.90
View source ↗ - Newsmarketbeat.com·7d ago·Neutral
LandBridge Q2 Earnings Call Highlights LandBridge NYSE: LB reported record second-quarter revenue of $66.8 million, up 41% from a year earlier and 31% sequentially, as produced-water activity and commercial development across its Delaware Basin acreage increased. The company reaffirmed its full-year 2026 adjusted EBITDA guidance of $210 million to $230 million.
View source ↗